monocrotaline

Monocrotaline is an 11-membered macrocyclic pyrrolizidine alkaloid extracted from the seeds of Crotalaria plants. It inhibits organic cation transporters OCT-1 and OCT-2, with IC50 values of 36.8 µM and 1.8 mM, respectively. Monocrotaline exhibits antitumor activity and shows certain cytotoxicity against liver cancer cells such as HepG2. It is also commonly used to induce pulmonary arterial hypertension models in rodents.

Monocrotaline N-Oxide is a monocrotaline metabolite.

Dehydromonocrotaline (Monocrotaline pyrrole) is a metabolite of Monocrotaline. It acts as an alkylating agent, capable of reacting with DNA, exhibiting cytotoxicity, and causing damage to both the liver and lungs.

Monocrotaline N-Oxide (Standard) is a reference standard for research and analysis in studies involving Monocrotaline N-Oxide. Monocrotaline N-Oxide is a monocrotaline metabolite.

Monocrotaline (Standard) is a reference standard for research and analysis in studies involving Monocrotaline. Monocrotaline is an 11-membered macrocyclic pyrrolizidine alkaloid extracted from the seeds of Crotalaria plants. It inhibits organic cation transporters OCT-1 and OCT-2, with IC50 values of 36.8 µM and 1.8 mM, respectively. Monocrotaline exhibits antitumor activity and shows certain cytotoxicity against liver cancer cells such as HepG2. It is also commonly used to induce pulmonary arterial hypertension models in rodents.

LASSBio-1366 is an agonist of adenosine A2a receptor that acts by attenuating the progression of monocrotaline-induced pulmonary hypertension.

D-Tetrahydropalmatine is a organic cation transporter 1 (OCT1) inhibitor, it can obviously inhibit the uptake of monocrotaline (MCT) in MDCK-hOCT1 cells and isolate rat primary hepatocytes, and attenuate the viability reduction and LDH release of the prim

ET Receptor Antagonist 1 (compound 16h), with an IC50 value of 0.18 nM, is an orally active agent that can be utilized for pulmonary arterial hypertension (PAH) research. It has demonstrated efficacy in mitigating monocrotaline-induced PAH in a rat model [1].

ET Receptor Antagonist 2 (Compound 16j) is an orally active ET receptor antagonist with an IC50 of 0.22 nM, suitable for pulmonary arterial hypertension (PAH) research. It has been shown to mitigate monocrotaline-induced PAH in a rat model [1].

"ET receptor antagonist 3 (compound 17d) is an orally active ET receptor antagonist with an IC50 of 0.26 nM, utilized for pulmonary arterial hypertension (PAH) research. This compound demonstrates efficacy in mitigating monocrotaline-induced PAH in a rat model [1]."

Getagozumab is a humanized IgG4-kappa monoclonal antibody that specifically targets endothelin receptor type A (EDNRA) with potent antagonistic activity. Getagozumab significantly lowered pulmonary arterial pressure in both hypoxia-induced and monocrotaline (MCT)-induced pulmonary arterial hypertension (PAH) monkey models and further attenuated the associated pulmonary arterial and right ventricular hypertrophy.